| Page 14 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial

Summary
Background
Access to allogeneic haematopoietic stem-cell transplantation (HSCT) remains challenging for older patients (aged >60 years) with acute myeloid leukaemia. We aimed to evaluate the efficacy of venetoclax plus decitabine as first-line therapy and bridge to transplantation in this patient population.
Methods

Exercise Treatment as Part of Multidisciplinary Whole Person Care in Oncology

Several national agencies, including the American Society of Clinical Oncology (ASCO), recommend the prescription of exercise for patients diagnosed with cancer.1,2 The evidence base for this recommendation is derived from studies that showed exercise-related improvements in patient-reported outcomes (PROs), treatment-associated adverse effects, cardiorespiratory fitness (CRF), and overall physical functioning.3-6 Additionally, exercise may have direct anticancer effects and indirect effects by synergizing standard cancer therapies.7,8 Despite these benefits, the implementation of exercise

Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents

Author(s): 
Garcia-Manero G, Matsuno RK, McBride A, Mohammed H, Idryo D, Broome R, Herriman A, Johnson T, Wilkinson K, Schrag A, Johanson C, Izano M, Makinde A, Mukherjee S
Primary Author: 
Garcia-Manero G
Journal Title: 
Clinical Lymphoma, Myeloma & Leukemia
Original Publication Date: 
Sep 2024

Introduction: Real-world studies of lower-risk

Bone Marrow Disease(s): 

Myelodysplastic Syndromes Treatment (PDQ®): Health Professional Version

Author(s): 
PDQ Adult Treatment Editorial Board
Primary Author: 
PDQ Adult Treatment Editorial Board
Journal Title: 
PDQ Cancer Information Summaries
Original Publication Date: 
Sep 2024

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of

Bone Marrow Disease(s):